nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCG2—Vismodegib—skin cancer	0.0875	0.172	CbGbCtD
Ponatinib—ABCG2—Vemurafenib—skin cancer	0.0692	0.136	CbGbCtD
Ponatinib—CYP2C8—Vismodegib—skin cancer	0.0466	0.0919	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—skin cancer	0.046	0.0906	CbGbCtD
Ponatinib—ABCB1—Vismodegib—skin cancer	0.0316	0.0622	CbGbCtD
Ponatinib—ABCG2—Fluorouracil—skin cancer	0.0311	0.0612	CbGbCtD
Ponatinib—CYP3A4—Temozolomide—skin cancer	0.0273	0.0537	CbGbCtD
Ponatinib—CYP3A4—Imiquimod—skin cancer	0.0273	0.0537	CbGbCtD
Ponatinib—ABCG2—Docetaxel—skin cancer	0.0237	0.0468	CbGbCtD
Ponatinib—CYP2D6—Vemurafenib—skin cancer	0.0235	0.0463	CbGbCtD
Ponatinib—CYP3A4—Vismodegib—skin cancer	0.0189	0.0373	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—skin cancer	0.0166	0.0327	CbGbCtD
Ponatinib—CYP2C8—Fluorouracil—skin cancer	0.0166	0.0326	CbGbCtD
Ponatinib—CYP3A4—Vemurafenib—skin cancer	0.0149	0.0294	CbGbCtD
Ponatinib—CYP3A5—Docetaxel—skin cancer	0.0132	0.0259	CbGbCtD
Ponatinib—ABCB1—Docetaxel—skin cancer	0.00856	0.0169	CbGbCtD
Ponatinib—FGFR3—appendage—skin cancer	0.00537	0.0466	CbGeAlD
Ponatinib—CYP3A4—Docetaxel—skin cancer	0.00513	0.0101	CbGbCtD
Ponatinib—PDGFRA—penis—skin cancer	0.00472	0.0409	CbGeAlD
Ponatinib—FGFR3—skin epidermis—skin cancer	0.00447	0.0388	CbGeAlD
Ponatinib—Nilotinib—BRAF—skin cancer	0.0037	1	CrCbGaD
Ponatinib—KDR—hindlimb—skin cancer	0.00321	0.0279	CbGeAlD
Ponatinib—FGFR3—hair follicle—skin cancer	0.00319	0.0277	CbGeAlD
Ponatinib—FGFR2—skin epidermis—skin cancer	0.00293	0.0254	CbGeAlD
Ponatinib—KDR—appendage—skin cancer	0.00276	0.0239	CbGeAlD
Ponatinib—FGFR4—connective tissue—skin cancer	0.00225	0.0195	CbGeAlD
Ponatinib—TEK—endothelium—skin cancer	0.00204	0.0177	CbGeAlD
Ponatinib—KIT—skin epidermis—skin cancer	0.00203	0.0176	CbGeAlD
Ponatinib—TEK—blood vessel—skin cancer	0.00188	0.0163	CbGeAlD
Ponatinib—BCR—nipple—skin cancer	0.00187	0.0162	CbGeAlD
Ponatinib—SRC—endothelium—skin cancer	0.00181	0.0157	CbGeAlD
Ponatinib—SRC—blood vessel—skin cancer	0.00167	0.0145	CbGeAlD
Ponatinib—KDR—endothelium—skin cancer	0.00166	0.0144	CbGeAlD
Ponatinib—FGFR4—female reproductive system—skin cancer	0.00158	0.0138	CbGeAlD
Ponatinib—LYN—connective tissue—skin cancer	0.00154	0.0134	CbGeAlD
Ponatinib—KDR—blood vessel—skin cancer	0.00153	0.0133	CbGeAlD
Ponatinib—FGFR3—connective tissue—skin cancer	0.00153	0.0133	CbGeAlD
Ponatinib—LCK—nipple—skin cancer	0.00149	0.0129	CbGeAlD
Ponatinib—KIT—endothelium—skin cancer	0.00147	0.0128	CbGeAlD
Ponatinib—RET—neck—skin cancer	0.00147	0.0128	CbGeAlD
Ponatinib—FGFR3—epithelium—skin cancer	0.00146	0.0126	CbGeAlD
Ponatinib—FGFR2—neck—skin cancer	0.0014	0.0122	CbGeAlD
Ponatinib—FGFR3—skin of body—skin cancer	0.00138	0.012	CbGeAlD
Ponatinib—KIT—blood vessel—skin cancer	0.00136	0.0118	CbGeAlD
Ponatinib—FGFR4—head—skin cancer	0.00132	0.0115	CbGeAlD
Ponatinib—FLT3—connective tissue—skin cancer	0.00132	0.0114	CbGeAlD
Ponatinib—FGFR3—mammalian vulva—skin cancer	0.00126	0.011	CbGeAlD
Ponatinib—LYN—lymphoid tissue—skin cancer	0.00113	0.00978	CbGeAlD
Ponatinib—KDR—nipple—skin cancer	0.00111	0.00962	CbGeAlD
Ponatinib—KDR—neck—skin cancer	0.0011	0.00952	CbGeAlD
Ponatinib—BCR—mammalian vulva—skin cancer	0.00109	0.00948	CbGeAlD
Ponatinib—FGFR3—female reproductive system—skin cancer	0.00108	0.00938	CbGeAlD
Ponatinib—RET—connective tissue—skin cancer	0.00106	0.00917	CbGeAlD
Ponatinib—FGFR2—connective tissue—skin cancer	0.001	0.00871	CbGeAlD
Ponatinib—RET—epithelium—skin cancer	0.001	0.0087	CbGeAlD
Ponatinib—KIT—nipple—skin cancer	0.000983	0.00853	CbGeAlD
Ponatinib—KIT—neck—skin cancer	0.000973	0.00844	CbGeAlD
Ponatinib—FGFR1—mammalian vulva—skin cancer	0.000972	0.00844	CbGeAlD
Ponatinib—BCR—lymphoid tissue—skin cancer	0.00097	0.00842	CbGeAlD
Ponatinib—FLT3—lymphoid tissue—skin cancer	0.000963	0.00836	CbGeAlD
Ponatinib—TEK—connective tissue—skin cancer	0.000962	0.00835	CbGeAlD
Ponatinib—FGFR2—epithelium—skin cancer	0.000953	0.00827	CbGeAlD
Ponatinib—BCR—female reproductive system—skin cancer	0.000936	0.00812	CbGeAlD
Ponatinib—FLT3—female reproductive system—skin cancer	0.000929	0.00806	CbGeAlD
Ponatinib—FGFR4—lymph node—skin cancer	0.000927	0.00805	CbGeAlD
Ponatinib—TEK—epithelium—skin cancer	0.000914	0.00793	CbGeAlD
Ponatinib—LYN—head—skin cancer	0.000908	0.00788	CbGeAlD
Ponatinib—FGFR2—skin of body—skin cancer	0.000906	0.00786	CbGeAlD
Ponatinib—FGFR3—head—skin cancer	0.000904	0.00784	CbGeAlD
Ponatinib—PDGFRA—connective tissue—skin cancer	0.000872	0.00757	CbGeAlD
Ponatinib—LCK—mammalian vulva—skin cancer	0.00087	0.00755	CbGeAlD
Ponatinib—ABL1—nipple—skin cancer	0.000856	0.00742	CbGeAlD
Ponatinib—SRC—connective tissue—skin cancer	0.000855	0.00742	CbGeAlD
Ponatinib—SRC—epithelium—skin cancer	0.000812	0.00704	CbGeAlD
Ponatinib—KDR—connective tissue—skin cancer	0.000787	0.00682	CbGeAlD
Ponatinib—BCR—head—skin cancer	0.000782	0.00678	CbGeAlD
Ponatinib—RET—lymphoid tissue—skin cancer	0.000772	0.0067	CbGeAlD
Ponatinib—SRC—skin of body—skin cancer	0.000772	0.0067	CbGeAlD
Ponatinib—KDR—epithelium—skin cancer	0.000747	0.00648	CbGeAlD
Ponatinib—FGFR2—female reproductive system—skin cancer	0.000708	0.00614	CbGeAlD
Ponatinib—TEK—lymphoid tissue—skin cancer	0.000704	0.00611	CbGeAlD
Ponatinib—KIT—connective tissue—skin cancer	0.000697	0.00605	CbGeAlD
Ponatinib—TEK—female reproductive system—skin cancer	0.000679	0.00589	CbGeAlD
Ponatinib—KIT—epithelium—skin cancer	0.000662	0.00574	CbGeAlD
Ponatinib—KDR—mammalian vulva—skin cancer	0.000648	0.00562	CbGeAlD
Ponatinib—PDGFRA—lymphoid tissue—skin cancer	0.000638	0.00553	CbGeAlD
Ponatinib—KIT—skin of body—skin cancer	0.000629	0.00546	CbGeAlD
Ponatinib—SRC—lymphoid tissue—skin cancer	0.000625	0.00542	CbGeAlD
Ponatinib—RET—head—skin cancer	0.000622	0.0054	CbGeAlD
Ponatinib—PDGFRA—female reproductive system—skin cancer	0.000615	0.00534	CbGeAlD
Ponatinib—ABL1—connective tissue—skin cancer	0.000607	0.00527	CbGeAlD
Ponatinib—SRC—female reproductive system—skin cancer	0.000603	0.00523	CbGeAlD
Ponatinib—FGFR2—head—skin cancer	0.000591	0.00513	CbGeAlD
Ponatinib—KDR—lymphoid tissue—skin cancer	0.000575	0.00499	CbGeAlD
Ponatinib—KIT—mammalian vulva—skin cancer	0.000574	0.00498	CbGeAlD
Ponatinib—TEK—head—skin cancer	0.000567	0.00492	CbGeAlD
Ponatinib—KDR—female reproductive system—skin cancer	0.000555	0.00481	CbGeAlD
Ponatinib—ABL1—skin of body—skin cancer	0.000548	0.00475	CbGeAlD
Ponatinib—BCR—lymph node—skin cancer	0.000547	0.00475	CbGeAlD
Ponatinib—FLT3—lymph node—skin cancer	0.000544	0.00472	CbGeAlD
Ponatinib—PDGFRA—head—skin cancer	0.000514	0.00446	CbGeAlD
Ponatinib—KIT—lymphoid tissue—skin cancer	0.00051	0.00442	CbGeAlD
Ponatinib—SRC—head—skin cancer	0.000504	0.00437	CbGeAlD
Ponatinib—ABL1—mammalian vulva—skin cancer	0.0005	0.00434	CbGeAlD
Ponatinib—KIT—female reproductive system—skin cancer	0.000492	0.00427	CbGeAlD
Ponatinib—FGFR1—lymph node—skin cancer	0.000487	0.00423	CbGeAlD
Ponatinib—KDR—head—skin cancer	0.000463	0.00402	CbGeAlD
Ponatinib—ABL1—lymphoid tissue—skin cancer	0.000444	0.00385	CbGeAlD
Ponatinib—RET—lymph node—skin cancer	0.000436	0.00378	CbGeAlD
Ponatinib—LCK—lymph node—skin cancer	0.000436	0.00378	CbGeAlD
Ponatinib—ABL1—female reproductive system—skin cancer	0.000428	0.00371	CbGeAlD
Ponatinib—KIT—head—skin cancer	0.000411	0.00356	CbGeAlD
Ponatinib—TEK—lymph node—skin cancer	0.000397	0.00345	CbGeAlD
Ponatinib—ABCB1—blood vessel—skin cancer	0.000368	0.00319	CbGeAlD
Ponatinib—PDGFRA—lymph node—skin cancer	0.00036	0.00312	CbGeAlD
Ponatinib—ABL1—head—skin cancer	0.000358	0.0031	CbGeAlD
Ponatinib—SRC—lymph node—skin cancer	0.000353	0.00306	CbGeAlD
Ponatinib—KDR—lymph node—skin cancer	0.000324	0.00282	CbGeAlD
Ponatinib—ABCG2—mammalian vulva—skin cancer	0.000315	0.00273	CbGeAlD
Ponatinib—KIT—lymph node—skin cancer	0.000288	0.0025	CbGeAlD
Ponatinib—CYP2C8—female reproductive system—skin cancer	0.000278	0.00241	CbGeAlD
Ponatinib—Chills—Bleomycin—skin cancer	0.000251	0.00117	CcSEcCtD
Ponatinib—ABL1—lymph node—skin cancer	0.00025	0.00217	CbGeAlD
Ponatinib—Cardiac failure congestive—Docetaxel—skin cancer	0.00025	0.00117	CcSEcCtD
Ponatinib—Dyspnoea—Imiquimod—skin cancer	0.000249	0.00117	CcSEcCtD
Ponatinib—Hepatobiliary disease—Temozolomide—skin cancer	0.000249	0.00116	CcSEcCtD
Ponatinib—Alopecia—Bleomycin—skin cancer	0.000247	0.00116	CcSEcCtD
Ponatinib—Dyspepsia—Imiquimod—skin cancer	0.000246	0.00115	CcSEcCtD
Ponatinib—Pneumonia—Fluorouracil—skin cancer	0.000244	0.00114	CcSEcCtD
Ponatinib—Erythema—Bleomycin—skin cancer	0.000244	0.00114	CcSEcCtD
Ponatinib—Decreased appetite—Imiquimod—skin cancer	0.000243	0.00114	CcSEcCtD
Ponatinib—Hot flush—Docetaxel—skin cancer	0.000242	0.00113	CcSEcCtD
Ponatinib—Infestation NOS—Fluorouracil—skin cancer	0.000242	0.00113	CcSEcCtD
Ponatinib—Infestation—Fluorouracil—skin cancer	0.000242	0.00113	CcSEcCtD
Ponatinib—Flushing—Dactinomycin—skin cancer	0.000242	0.00113	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Imiquimod—skin cancer	0.000242	0.00113	CcSEcCtD
Ponatinib—Fatigue—Imiquimod—skin cancer	0.000241	0.00113	CcSEcCtD
Ponatinib—Menopausal symptoms—Docetaxel—skin cancer	0.00024	0.00112	CcSEcCtD
Ponatinib—Atrial fibrillation—Docetaxel—skin cancer	0.000239	0.00112	CcSEcCtD
Ponatinib—Pain—Imiquimod—skin cancer	0.000239	0.00112	CcSEcCtD
Ponatinib—Acute coronary syndrome—Fluorouracil—skin cancer	0.000239	0.00112	CcSEcCtD
Ponatinib—Myocardial infarction—Fluorouracil—skin cancer	0.000237	0.00111	CcSEcCtD
Ponatinib—Neuropathy peripheral—Fluorouracil—skin cancer	0.000237	0.00111	CcSEcCtD
Ponatinib—Haemoglobin—Temozolomide—skin cancer	0.000237	0.00111	CcSEcCtD
Ponatinib—Stomatitis—Fluorouracil—skin cancer	0.000236	0.0011	CcSEcCtD
Ponatinib—Haemorrhage—Temozolomide—skin cancer	0.000236	0.0011	CcSEcCtD
Ponatinib—Urinary tract infection—Fluorouracil—skin cancer	0.000235	0.0011	CcSEcCtD
Ponatinib—Asthenia—Vemurafenib—skin cancer	0.000235	0.0011	CcSEcCtD
Ponatinib—Hypoaesthesia—Temozolomide—skin cancer	0.000235	0.0011	CcSEcCtD
Ponatinib—Chills—Dactinomycin—skin cancer	0.000234	0.0011	CcSEcCtD
Ponatinib—Oedema peripheral—Temozolomide—skin cancer	0.000232	0.00109	CcSEcCtD
Ponatinib—Cardiac failure—Docetaxel—skin cancer	0.000232	0.00109	CcSEcCtD
Ponatinib—Pruritus—Vemurafenib—skin cancer	0.000232	0.00109	CcSEcCtD
Ponatinib—Connective tissue disorder—Temozolomide—skin cancer	0.000232	0.00108	CcSEcCtD
Ponatinib—Lethargy—Docetaxel—skin cancer	0.000231	0.00108	CcSEcCtD
Ponatinib—Alopecia—Dactinomycin—skin cancer	0.000231	0.00108	CcSEcCtD
Ponatinib—Gastrointestinal pain—Imiquimod—skin cancer	0.000229	0.00107	CcSEcCtD
Ponatinib—Epistaxis—Fluorouracil—skin cancer	0.000228	0.00107	CcSEcCtD
Ponatinib—Hyponatraemia—Docetaxel—skin cancer	0.000228	0.00107	CcSEcCtD
Ponatinib—Visual impairment—Temozolomide—skin cancer	0.000227	0.00106	CcSEcCtD
Ponatinib—Erythema—Dactinomycin—skin cancer	0.000227	0.00106	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000227	0.00106	CcSEcCtD
Ponatinib—Pain in extremity—Docetaxel—skin cancer	0.000227	0.00106	CcSEcCtD
Ponatinib—Anaemia—Bleomycin—skin cancer	0.000225	0.00105	CcSEcCtD
Ponatinib—Diarrhoea—Vemurafenib—skin cancer	0.000224	0.00105	CcSEcCtD
Ponatinib—Migraine—Docetaxel—skin cancer	0.000223	0.00104	CcSEcCtD
Ponatinib—Abdominal pain—Imiquimod—skin cancer	0.000221	0.00103	CcSEcCtD
Ponatinib—Body temperature increased—Imiquimod—skin cancer	0.000221	0.00103	CcSEcCtD
Ponatinib—Eye disorder—Temozolomide—skin cancer	0.000221	0.00103	CcSEcCtD
Ponatinib—Flushing—Temozolomide—skin cancer	0.000219	0.00102	CcSEcCtD
Ponatinib—Cardiac disorder—Temozolomide—skin cancer	0.000219	0.00102	CcSEcCtD
Ponatinib—Haemoglobin—Fluorouracil—skin cancer	0.000219	0.00102	CcSEcCtD
Ponatinib—Leukopenia—Bleomycin—skin cancer	0.000218	0.00102	CcSEcCtD
Ponatinib—Haemorrhage—Fluorouracil—skin cancer	0.000217	0.00102	CcSEcCtD
Ponatinib—Dizziness—Vemurafenib—skin cancer	0.000217	0.00101	CcSEcCtD
Ponatinib—Hypoaesthesia—Fluorouracil—skin cancer	0.000216	0.00101	CcSEcCtD
Ponatinib—Angiopathy—Temozolomide—skin cancer	0.000214	0.001	CcSEcCtD
Ponatinib—Mediastinal disorder—Temozolomide—skin cancer	0.000213	0.000995	CcSEcCtD
Ponatinib—Cough—Bleomycin—skin cancer	0.000213	0.000994	CcSEcCtD
Ponatinib—Chills—Temozolomide—skin cancer	0.000212	0.00099	CcSEcCtD
Ponatinib—Dehydration—Docetaxel—skin cancer	0.000211	0.000987	CcSEcCtD
Ponatinib—Anaemia—Dactinomycin—skin cancer	0.00021	0.000982	CcSEcCtD
Ponatinib—Vomiting—Vemurafenib—skin cancer	0.000209	0.000976	CcSEcCtD
Ponatinib—Alopecia—Temozolomide—skin cancer	0.000209	0.000975	CcSEcCtD
Ponatinib—Dry skin—Docetaxel—skin cancer	0.000208	0.000973	CcSEcCtD
Ponatinib—Myalgia—Bleomycin—skin cancer	0.000207	0.00097	CcSEcCtD
Ponatinib—Rash—Vemurafenib—skin cancer	0.000207	0.000967	CcSEcCtD
Ponatinib—Mental disorder—Temozolomide—skin cancer	0.000207	0.000967	CcSEcCtD
Ponatinib—Dermatitis—Vemurafenib—skin cancer	0.000207	0.000967	CcSEcCtD
Ponatinib—Headache—Vemurafenib—skin cancer	0.000206	0.000961	CcSEcCtD
Ponatinib—Malnutrition—Temozolomide—skin cancer	0.000205	0.000961	CcSEcCtD
Ponatinib—Erythema—Temozolomide—skin cancer	0.000205	0.000961	CcSEcCtD
Ponatinib—Breast disorder—Docetaxel—skin cancer	0.000205	0.000959	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000204	0.000955	CcSEcCtD
Ponatinib—Leukopenia—Dactinomycin—skin cancer	0.000203	0.000951	CcSEcCtD
Ponatinib—Nasopharyngitis—Docetaxel—skin cancer	0.000203	0.000949	CcSEcCtD
Ponatinib—Asthenia—Imiquimod—skin cancer	0.000201	0.000939	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.0002	0.000936	CcSEcCtD
Ponatinib—Oedema—Bleomycin—skin cancer	0.000199	0.00093	CcSEcCtD
Ponatinib—Back pain—Temozolomide—skin cancer	0.000199	0.000929	CcSEcCtD
Ponatinib—Pruritus—Imiquimod—skin cancer	0.000198	0.000926	CcSEcCtD
Ponatinib—Infection—Bleomycin—skin cancer	0.000197	0.000924	CcSEcCtD
Ponatinib—Nausea—Vemurafenib—skin cancer	0.000195	0.000911	CcSEcCtD
Ponatinib—Thrombocytopenia—Bleomycin—skin cancer	0.000195	0.00091	CcSEcCtD
Ponatinib—Arrhythmia—Fluorouracil—skin cancer	0.000194	0.000909	CcSEcCtD
Ponatinib—Vision blurred—Temozolomide—skin cancer	0.000194	0.000906	CcSEcCtD
Ponatinib—Myalgia—Dactinomycin—skin cancer	0.000193	0.000904	CcSEcCtD
Ponatinib—Alopecia—Fluorouracil—skin cancer	0.000192	0.000899	CcSEcCtD
Ponatinib—Diarrhoea—Imiquimod—skin cancer	0.000191	0.000895	CcSEcCtD
Ponatinib—Angina pectoris—Docetaxel—skin cancer	0.000191	0.000893	CcSEcCtD
Ponatinib—Anaemia—Temozolomide—skin cancer	0.00019	0.000888	CcSEcCtD
Ponatinib—Erythema—Fluorouracil—skin cancer	0.000189	0.000885	CcSEcCtD
Ponatinib—CYP3A4—female reproductive system—skin cancer	0.000188	0.00163	CbGeAlD
Ponatinib—Pancytopenia—Docetaxel—skin cancer	0.000186	0.000871	CcSEcCtD
Ponatinib—Oedema—Dactinomycin—skin cancer	0.000185	0.000867	CcSEcCtD
Ponatinib—Dizziness—Imiquimod—skin cancer	0.000185	0.000865	CcSEcCtD
Ponatinib—CYP2D6—female reproductive system—skin cancer	0.000185	0.00161	CbGeAlD
Ponatinib—Infection—Dactinomycin—skin cancer	0.000184	0.000861	CcSEcCtD
Ponatinib—Leukopenia—Temozolomide—skin cancer	0.000184	0.00086	CcSEcCtD
Ponatinib—Neutropenia—Docetaxel—skin cancer	0.000183	0.000858	CcSEcCtD
Ponatinib—Thrombocytopenia—Dactinomycin—skin cancer	0.000181	0.000849	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000181	0.000847	CcSEcCtD
Ponatinib—Cough—Temozolomide—skin cancer	0.000179	0.000838	CcSEcCtD
Ponatinib—ABCB1—epithelium—skin cancer	0.000179	0.00155	CbGeAlD
Ponatinib—Paraesthesia—Bleomycin—skin cancer	0.000178	0.000835	CcSEcCtD
Ponatinib—Vision blurred—Fluorouracil—skin cancer	0.000178	0.000834	CcSEcCtD
Ponatinib—Vomiting—Imiquimod—skin cancer	0.000178	0.000832	CcSEcCtD
Ponatinib—Weight decreased—Docetaxel—skin cancer	0.000177	0.00083	CcSEcCtD
Ponatinib—Hypertension—Temozolomide—skin cancer	0.000177	0.00083	CcSEcCtD
Ponatinib—Dyspnoea—Bleomycin—skin cancer	0.000177	0.000829	CcSEcCtD
Ponatinib—Rash—Imiquimod—skin cancer	0.000176	0.000825	CcSEcCtD
Ponatinib—Dermatitis—Imiquimod—skin cancer	0.000176	0.000824	CcSEcCtD
Ponatinib—Pneumonia—Docetaxel—skin cancer	0.000176	0.000822	CcSEcCtD
Ponatinib—Headache—Imiquimod—skin cancer	0.000175	0.00082	CcSEcCtD
Ponatinib—Anaemia—Fluorouracil—skin cancer	0.000175	0.000818	CcSEcCtD
Ponatinib—Arthralgia—Temozolomide—skin cancer	0.000175	0.000818	CcSEcCtD
Ponatinib—Myalgia—Temozolomide—skin cancer	0.000175	0.000818	CcSEcCtD
Ponatinib—Infestation NOS—Docetaxel—skin cancer	0.000175	0.000818	CcSEcCtD
Ponatinib—Infestation—Docetaxel—skin cancer	0.000175	0.000818	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000174	0.000812	CcSEcCtD
Ponatinib—Decreased appetite—Bleomycin—skin cancer	0.000173	0.000808	CcSEcCtD
Ponatinib—Acute coronary syndrome—Docetaxel—skin cancer	0.000172	0.000806	CcSEcCtD
Ponatinib—Myocardial infarction—Docetaxel—skin cancer	0.000171	0.000802	CcSEcCtD
Ponatinib—Neuropathy peripheral—Docetaxel—skin cancer	0.000171	0.000802	CcSEcCtD
Ponatinib—Dry mouth—Temozolomide—skin cancer	0.000171	0.0008	CcSEcCtD
Ponatinib—Stomatitis—Docetaxel—skin cancer	0.00017	0.000797	CcSEcCtD
Ponatinib—Jaundice—Docetaxel—skin cancer	0.00017	0.000797	CcSEcCtD
Ponatinib—Pain—Bleomycin—skin cancer	0.00017	0.000795	CcSEcCtD
Ponatinib—Leukopenia—Fluorouracil—skin cancer	0.000169	0.000792	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000169	0.00079	CcSEcCtD
Ponatinib—Oedema—Temozolomide—skin cancer	0.000168	0.000784	CcSEcCtD
Ponatinib—Infection—Temozolomide—skin cancer	0.000167	0.000779	CcSEcCtD
Ponatinib—Nausea—Imiquimod—skin cancer	0.000166	0.000777	CcSEcCtD
Ponatinib—Hepatobiliary disease—Docetaxel—skin cancer	0.000165	0.000773	CcSEcCtD
Ponatinib—Epistaxis—Docetaxel—skin cancer	0.000165	0.000771	CcSEcCtD
Ponatinib—Nervous system disorder—Temozolomide—skin cancer	0.000164	0.000769	CcSEcCtD
Ponatinib—Thrombocytopenia—Temozolomide—skin cancer	0.000164	0.000768	CcSEcCtD
Ponatinib—Skin disorder—Temozolomide—skin cancer	0.000163	0.000762	CcSEcCtD
Ponatinib—Hyperhidrosis—Temozolomide—skin cancer	0.000162	0.000758	CcSEcCtD
Ponatinib—Myalgia—Fluorouracil—skin cancer	0.000161	0.000754	CcSEcCtD
Ponatinib—Decreased appetite—Dactinomycin—skin cancer	0.000161	0.000754	CcSEcCtD
Ponatinib—Fatigue—Dactinomycin—skin cancer	0.00016	0.000748	CcSEcCtD
Ponatinib—Pain—Dactinomycin—skin cancer	0.000159	0.000741	CcSEcCtD
Ponatinib—ABCG2—lymph node—skin cancer	0.000158	0.00137	CbGeAlD
Ponatinib—Haemoglobin—Docetaxel—skin cancer	0.000158	0.000738	CcSEcCtD
Ponatinib—Body temperature increased—Bleomycin—skin cancer	0.000157	0.000735	CcSEcCtD
Ponatinib—Haemorrhage—Docetaxel—skin cancer	0.000157	0.000734	CcSEcCtD
Ponatinib—Hypoaesthesia—Docetaxel—skin cancer	0.000156	0.00073	CcSEcCtD
Ponatinib—ABCB1—mammalian vulva—skin cancer	0.000155	0.00135	CbGeAlD
Ponatinib—Oedema peripheral—Docetaxel—skin cancer	0.000155	0.000723	CcSEcCtD
Ponatinib—CYP2D6—head—skin cancer	0.000155	0.00134	CbGeAlD
Ponatinib—Oedema—Fluorouracil—skin cancer	0.000154	0.000723	CcSEcCtD
Ponatinib—Connective tissue disorder—Docetaxel—skin cancer	0.000154	0.000721	CcSEcCtD
Ponatinib—Infection—Fluorouracil—skin cancer	0.000153	0.000718	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000153	0.000714	CcSEcCtD
Ponatinib—Insomnia—Temozolomide—skin cancer	0.000152	0.000709	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dactinomycin—skin cancer	0.000152	0.000709	CcSEcCtD
Ponatinib—Nervous system disorder—Fluorouracil—skin cancer	0.000151	0.000709	CcSEcCtD
Ponatinib—Thrombocytopenia—Fluorouracil—skin cancer	0.000151	0.000707	CcSEcCtD
Ponatinib—Visual impairment—Docetaxel—skin cancer	0.000151	0.000707	CcSEcCtD
Ponatinib—Paraesthesia—Temozolomide—skin cancer	0.000151	0.000704	CcSEcCtD
Ponatinib—Dyspnoea—Temozolomide—skin cancer	0.000149	0.000699	CcSEcCtD
Ponatinib—Dyspepsia—Temozolomide—skin cancer	0.000148	0.00069	CcSEcCtD
Ponatinib—Eye disorder—Docetaxel—skin cancer	0.000147	0.000686	CcSEcCtD
Ponatinib—Body temperature increased—Dactinomycin—skin cancer	0.000147	0.000685	CcSEcCtD
Ponatinib—Abdominal pain—Dactinomycin—skin cancer	0.000147	0.000685	CcSEcCtD
Ponatinib—Decreased appetite—Temozolomide—skin cancer	0.000146	0.000682	CcSEcCtD
Ponatinib—Cardiac disorder—Docetaxel—skin cancer	0.000146	0.000681	CcSEcCtD
Ponatinib—Flushing—Docetaxel—skin cancer	0.000146	0.000681	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Temozolomide—skin cancer	0.000145	0.000677	CcSEcCtD
Ponatinib—Fatigue—Temozolomide—skin cancer	0.000145	0.000676	CcSEcCtD
Ponatinib—Constipation—Temozolomide—skin cancer	0.000143	0.000671	CcSEcCtD
Ponatinib—Pain—Temozolomide—skin cancer	0.000143	0.000671	CcSEcCtD
Ponatinib—Asthenia—Bleomycin—skin cancer	0.000143	0.000667	CcSEcCtD
Ponatinib—Angiopathy—Docetaxel—skin cancer	0.000142	0.000666	CcSEcCtD
Ponatinib—Mediastinal disorder—Docetaxel—skin cancer	0.000141	0.000662	CcSEcCtD
Ponatinib—Chills—Docetaxel—skin cancer	0.000141	0.000659	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000141	0.000658	CcSEcCtD
Ponatinib—Pruritus—Bleomycin—skin cancer	0.000141	0.000658	CcSEcCtD
Ponatinib—Arrhythmia—Docetaxel—skin cancer	0.00014	0.000656	CcSEcCtD
Ponatinib—Insomnia—Fluorouracil—skin cancer	0.00014	0.000654	CcSEcCtD
Ponatinib—Paraesthesia—Fluorouracil—skin cancer	0.000139	0.000649	CcSEcCtD
Ponatinib—Alopecia—Docetaxel—skin cancer	0.000139	0.000649	CcSEcCtD
Ponatinib—ABCB1—lymphoid tissue—skin cancer	0.000138	0.0012	CbGeAlD
Ponatinib—Dyspnoea—Fluorouracil—skin cancer	0.000138	0.000644	CcSEcCtD
Ponatinib—Mental disorder—Docetaxel—skin cancer	0.000137	0.000643	CcSEcCtD
Ponatinib—Gastrointestinal pain—Temozolomide—skin cancer	0.000137	0.000641	CcSEcCtD
Ponatinib—Erythema—Docetaxel—skin cancer	0.000137	0.000639	CcSEcCtD
Ponatinib—Malnutrition—Docetaxel—skin cancer	0.000137	0.000639	CcSEcCtD
Ponatinib—Dyspepsia—Fluorouracil—skin cancer	0.000136	0.000636	CcSEcCtD
Ponatinib—Decreased appetite—Fluorouracil—skin cancer	0.000134	0.000628	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000133	0.000624	CcSEcCtD
Ponatinib—ABCB1—female reproductive system—skin cancer	0.000133	0.00115	CbGeAlD
Ponatinib—Asthenia—Dactinomycin—skin cancer	0.000133	0.000622	CcSEcCtD
Ponatinib—Abdominal pain—Temozolomide—skin cancer	0.000133	0.00062	CcSEcCtD
Ponatinib—Body temperature increased—Temozolomide—skin cancer	0.000133	0.00062	CcSEcCtD
Ponatinib—Back pain—Docetaxel—skin cancer	0.000132	0.000618	CcSEcCtD
Ponatinib—Pain—Fluorouracil—skin cancer	0.000132	0.000618	CcSEcCtD
Ponatinib—Muscle spasms—Docetaxel—skin cancer	0.000131	0.000614	CcSEcCtD
Ponatinib—Diarrhoea—Dactinomycin—skin cancer	0.000127	0.000593	CcSEcCtD
Ponatinib—Vomiting—Bleomycin—skin cancer	0.000126	0.000591	CcSEcCtD
Ponatinib—Anaemia—Docetaxel—skin cancer	0.000126	0.000591	CcSEcCtD
Ponatinib—Rash—Bleomycin—skin cancer	0.000125	0.000586	CcSEcCtD
Ponatinib—Dermatitis—Bleomycin—skin cancer	0.000125	0.000586	CcSEcCtD
Ponatinib—Leukopenia—Docetaxel—skin cancer	0.000122	0.000572	CcSEcCtD
Ponatinib—Body temperature increased—Fluorouracil—skin cancer	0.000122	0.000571	CcSEcCtD
Ponatinib—Asthenia—Temozolomide—skin cancer	0.00012	0.000563	CcSEcCtD
Ponatinib—Cough—Docetaxel—skin cancer	0.000119	0.000558	CcSEcCtD
Ponatinib—Pruritus—Temozolomide—skin cancer	0.000119	0.000555	CcSEcCtD
Ponatinib—Nausea—Bleomycin—skin cancer	0.000118	0.000552	CcSEcCtD
Ponatinib—Hypertension—Docetaxel—skin cancer	0.000118	0.000552	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—skin cancer	0.000118	0.000551	CcSEcCtD
Ponatinib—Rash—Dactinomycin—skin cancer	0.000117	0.000547	CcSEcCtD
Ponatinib—Arthralgia—Docetaxel—skin cancer	0.000116	0.000544	CcSEcCtD
Ponatinib—Myalgia—Docetaxel—skin cancer	0.000116	0.000544	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000116	0.00054	CcSEcCtD
Ponatinib—Diarrhoea—Temozolomide—skin cancer	0.000115	0.000537	CcSEcCtD
Ponatinib—Dry mouth—Docetaxel—skin cancer	0.000114	0.000532	CcSEcCtD
Ponatinib—Oedema—Docetaxel—skin cancer	0.000111	0.000522	CcSEcCtD
Ponatinib—ABCB1—head—skin cancer	0.000111	0.000965	CbGeAlD
Ponatinib—Dizziness—Temozolomide—skin cancer	0.000111	0.000519	CcSEcCtD
Ponatinib—Infection—Docetaxel—skin cancer	0.000111	0.000518	CcSEcCtD
Ponatinib—Nausea—Dactinomycin—skin cancer	0.00011	0.000515	CcSEcCtD
Ponatinib—Nervous system disorder—Docetaxel—skin cancer	0.000109	0.000511	CcSEcCtD
Ponatinib—Pruritus—Fluorouracil—skin cancer	0.000109	0.000511	CcSEcCtD
Ponatinib—Thrombocytopenia—Docetaxel—skin cancer	0.000109	0.000511	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—skin cancer	0.000108	0.000507	CcSEcCtD
Ponatinib—Vomiting—Temozolomide—skin cancer	0.000107	0.000499	CcSEcCtD
Ponatinib—Rash—Temozolomide—skin cancer	0.000106	0.000494	CcSEcCtD
Ponatinib—Diarrhoea—Fluorouracil—skin cancer	0.000106	0.000494	CcSEcCtD
Ponatinib—Dermatitis—Temozolomide—skin cancer	0.000106	0.000494	CcSEcCtD
Ponatinib—Headache—Temozolomide—skin cancer	0.000105	0.000491	CcSEcCtD
Ponatinib—Dizziness—Fluorouracil—skin cancer	0.000102	0.000478	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000102	0.000475	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—skin cancer	0.000101	0.000472	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—skin cancer	0.0001	0.000468	CcSEcCtD
Ponatinib—Nausea—Temozolomide—skin cancer	9.96e-05	0.000466	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—skin cancer	9.94e-05	0.000465	CcSEcCtD
Ponatinib—Vomiting—Fluorouracil—skin cancer	9.82e-05	0.000459	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—skin cancer	9.81e-05	0.000459	CcSEcCtD
Ponatinib—Rash—Fluorouracil—skin cancer	9.74e-05	0.000456	CcSEcCtD
Ponatinib—Dermatitis—Fluorouracil—skin cancer	9.73e-05	0.000455	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—skin cancer	9.69e-05	0.000453	CcSEcCtD
Ponatinib—Headache—Fluorouracil—skin cancer	9.68e-05	0.000453	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—skin cancer	9.63e-05	0.00045	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—skin cancer	9.61e-05	0.00045	CcSEcCtD
Ponatinib—Pain—Docetaxel—skin cancer	9.53e-05	0.000446	CcSEcCtD
Ponatinib—Constipation—Docetaxel—skin cancer	9.53e-05	0.000446	CcSEcCtD
Ponatinib—Nausea—Fluorouracil—skin cancer	9.18e-05	0.000429	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—skin cancer	9.12e-05	0.000426	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—skin cancer	8.81e-05	0.000412	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—skin cancer	8.81e-05	0.000412	CcSEcCtD
Ponatinib—Asthenia—Docetaxel—skin cancer	8e-05	0.000374	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—skin cancer	7.89e-05	0.000369	CcSEcCtD
Ponatinib—ABCB1—lymph node—skin cancer	7.78e-05	0.000675	CbGeAlD
Ponatinib—Diarrhoea—Docetaxel—skin cancer	7.63e-05	0.000357	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—skin cancer	7.37e-05	0.000345	CcSEcCtD
Ponatinib—Vomiting—Docetaxel—skin cancer	7.09e-05	0.000332	CcSEcCtD
Ponatinib—Rash—Docetaxel—skin cancer	7.03e-05	0.000329	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—skin cancer	7.02e-05	0.000329	CcSEcCtD
Ponatinib—Headache—Docetaxel—skin cancer	6.98e-05	0.000327	CcSEcCtD
Ponatinib—Nausea—Docetaxel—skin cancer	6.62e-05	0.00031	CcSEcCtD
Ponatinib—LYN—Innate Immune System—NRAS—skin cancer	1.43e-05	8.93e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—NRAS—skin cancer	1.42e-05	8.89e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—KRAS—skin cancer	1.41e-05	8.85e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—KRAS—skin cancer	1.41e-05	8.84e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CSPG4—skin cancer	1.41e-05	8.83e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—skin cancer	1.4e-05	8.75e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—KRAS—skin cancer	1.39e-05	8.73e-05	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—IL6—skin cancer	1.39e-05	8.73e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—KRAS—skin cancer	1.39e-05	8.71e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—KRAS—skin cancer	1.39e-05	8.7e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—BRAF—skin cancer	1.39e-05	8.68e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—BRAF—skin cancer	1.38e-05	8.66e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—KRAS—skin cancer	1.38e-05	8.66e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—NRAS—skin cancer	1.37e-05	8.57e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—KRAS—skin cancer	1.36e-05	8.53e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SMO—skin cancer	1.36e-05	8.53e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTCH1—skin cancer	1.36e-05	8.53e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—NRAS—skin cancer	1.36e-05	8.51e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—KRAS—skin cancer	1.36e-05	8.49e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ENO2—skin cancer	1.35e-05	8.44e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—ERCC2—skin cancer	1.35e-05	8.43e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—HRAS—skin cancer	1.34e-05	8.42e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—HRAS—skin cancer	1.34e-05	8.4e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—KRAS—skin cancer	1.34e-05	8.39e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—HRAS—skin cancer	1.34e-05	8.37e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—KRAS—skin cancer	1.34e-05	8.36e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—HRAS—skin cancer	1.33e-05	8.31e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTGER4—skin cancer	1.33e-05	8.31e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FOXO4—skin cancer	1.32e-05	8.29e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—BRAF—skin cancer	1.32e-05	8.26e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TERT—skin cancer	1.32e-05	8.24e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—NRAS—skin cancer	1.3e-05	8.13e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TERT—skin cancer	1.29e-05	8.09e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—NRAS—skin cancer	1.29e-05	8.06e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—IL6—skin cancer	1.29e-05	8.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—IL6—skin cancer	1.28e-05	8.04e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IL6—skin cancer	1.28e-05	8.01e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.28e-05	7.99e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—HRAS—skin cancer	1.27e-05	7.96e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—IL6—skin cancer	1.27e-05	7.95e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—KRAS—skin cancer	1.27e-05	7.93e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TERT—skin cancer	1.26e-05	7.91e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—HRAS—skin cancer	1.25e-05	7.82e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—KRAS—skin cancer	1.23e-05	7.68e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TERT—skin cancer	1.23e-05	7.68e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TERT—skin cancer	1.22e-05	7.66e-05	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—HRAS—skin cancer	1.22e-05	7.65e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—KRAS—skin cancer	1.22e-05	7.65e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—IL6—skin cancer	1.22e-05	7.62e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—skin cancer	1.21e-05	7.58e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—skin cancer	1.21e-05	7.55e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PTGS2—skin cancer	1.2e-05	7.52e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—HRAS—skin cancer	1.2e-05	7.52e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—HRAS—skin cancer	1.2e-05	7.51e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—IL6—skin cancer	1.2e-05	7.49e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERCC2—skin cancer	1.19e-05	7.47e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—HRAS—skin cancer	1.19e-05	7.42e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—HRAS—skin cancer	1.18e-05	7.4e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—HRAS—skin cancer	1.18e-05	7.39e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PTGS2—skin cancer	1.18e-05	7.39e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—KRAS—skin cancer	1.18e-05	7.38e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—HRAS—skin cancer	1.18e-05	7.36e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FOXO4—skin cancer	1.17e-05	7.34e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—NRAS—skin cancer	1.17e-05	7.33e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—KRAS—skin cancer	1.17e-05	7.33e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—NRAS—skin cancer	1.17e-05	7.32e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ENO2—skin cancer	1.17e-05	7.31e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—HRAS—skin cancer	1.16e-05	7.25e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—HRAS—skin cancer	1.15e-05	7.22e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—IL6—skin cancer	1.15e-05	7.2e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—NRAS—skin cancer	1.15e-05	7.19e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLIN2—skin cancer	1.14e-05	7.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—HRAS—skin cancer	1.14e-05	7.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—HRAS—skin cancer	1.14e-05	7.11e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—IL6—skin cancer	1.13e-05	7.1e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.13e-05	7.1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—IL6—skin cancer	1.13e-05	7.09e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—IL6—skin cancer	1.13e-05	7.08e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—IL6—skin cancer	1.13e-05	7.04e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—NRAS—skin cancer	1.12e-05	7.03e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PTGS2—skin cancer	1.12e-05	7.01e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TERT—skin cancer	1.12e-05	7e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—KRAS—skin cancer	1.12e-05	6.99e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PTGS2—skin cancer	1.12e-05	6.99e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KRAS—skin cancer	1.11e-05	6.94e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ERCC2—skin cancer	1.09e-05	6.84e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TERT—skin cancer	1.08e-05	6.75e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HRAS—skin cancer	1.08e-05	6.74e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—HRAS—skin cancer	1.04e-05	6.53e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—BRAF—skin cancer	1.04e-05	6.52e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—HRAS—skin cancer	1.04e-05	6.5e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—NRAS—skin cancer	1.03e-05	6.48e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—skin cancer	1.03e-05	6.45e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—BRAF—skin cancer	1.02e-05	6.41e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ENO2—skin cancer	1.02e-05	6.37e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—NRAS—skin cancer	1.01e-05	6.34e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—KRAS—skin cancer	1.01e-05	6.31e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—KRAS—skin cancer	1.01e-05	6.3e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HRAS—skin cancer	1e-05	6.27e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—BRAF—skin cancer	1e-05	6.26e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—skin cancer	9.98e-06	6.25e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—NRAS—skin cancer	9.94e-06	6.23e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—HRAS—skin cancer	9.94e-06	6.23e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—skin cancer	9.94e-06	6.22e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—NRAS—skin cancer	9.93e-06	6.22e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—skin cancer	9.93e-06	6.22e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PTGS2—skin cancer	9.91e-06	6.21e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—KRAS—skin cancer	9.89e-06	6.19e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—skin cancer	9.84e-06	6.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—BRAF—skin cancer	9.71e-06	6.08e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—BRAF—skin cancer	9.68e-06	6.06e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KRAS—skin cancer	9.66e-06	6.05e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO2—skin cancer	9.58e-06	6e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NRAS—skin cancer	9.52e-06	5.96e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—skin cancer	9.52e-06	5.96e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—HRAS—skin cancer	9.5e-06	5.95e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—NRAS—skin cancer	9.44e-06	5.91e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—HRAS—skin cancer	9.41e-06	5.89e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—NRAS—skin cancer	9.41e-06	5.89e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NRAS—skin cancer	9.35e-06	5.85e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CSPG4—skin cancer	9.22e-06	5.77e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—NRAS—skin cancer	9.18e-06	5.75e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.13e-06	5.72e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—skin cancer	9.01e-06	5.64e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KRAS—skin cancer	8.9e-06	5.57e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—BRAF—skin cancer	8.85e-06	5.54e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TERT—skin cancer	8.84e-06	5.54e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—skin cancer	8.79e-06	5.5e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KRAS—skin cancer	8.72e-06	5.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NRAS—skin cancer	8.71e-06	5.46e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NRAS—skin cancer	8.69e-06	5.44e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—HRAS—skin cancer	8.57e-06	5.37e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—KRAS—skin cancer	8.56e-06	5.36e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KRAS—skin cancer	8.55e-06	5.35e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—HRAS—skin cancer	8.55e-06	5.35e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—BRAF—skin cancer	8.54e-06	5.35e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—skin cancer	8.41e-06	5.26e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—NRAS—skin cancer	8.3e-06	5.2e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NRAS—skin cancer	8.29e-06	5.19e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NRAS—skin cancer	8.26e-06	5.18e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—skin cancer	8.21e-06	5.14e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—skin cancer	8.2e-06	5.14e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KRAS—skin cancer	8.19e-06	5.13e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—skin cancer	8.18e-06	5.12e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KRAS—skin cancer	8.12e-06	5.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KRAS—skin cancer	8.1e-06	5.07e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—skin cancer	8.08e-06	5.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KRAS—skin cancer	8.05e-06	5.04e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—KRAS—skin cancer	7.9e-06	4.95e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ERCC2—skin cancer	7.83e-06	4.9e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TERT—skin cancer	7.83e-06	4.9e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—skin cancer	7.57e-06	4.74e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—skin cancer	7.5e-06	4.7e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—skin cancer	7.48e-06	4.68e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—skin cancer	7.41e-06	4.64e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—skin cancer	7.28e-06	4.56e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—skin cancer	7.28e-06	4.56e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—skin cancer	7.27e-06	4.55e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—skin cancer	7.24e-06	4.54e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—skin cancer	7.15e-06	4.48e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—skin cancer	7.15e-06	4.47e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—skin cancer	7.14e-06	4.47e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—skin cancer	7.11e-06	4.45e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—skin cancer	7.09e-06	4.44e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—BRAF—skin cancer	7e-06	4.38e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—skin cancer	6.96e-06	4.36e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—skin cancer	6.96e-06	4.36e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—skin cancer	6.9e-06	4.32e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—skin cancer	6.89e-06	4.31e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—skin cancer	6.84e-06	4.28e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—skin cancer	6.81e-06	4.26e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ERCC2—skin cancer	6.78e-06	4.25e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—skin cancer	6.72e-06	4.21e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—skin cancer	6.66e-06	4.17e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—skin cancer	6.61e-06	4.14e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—skin cancer	6.59e-06	4.13e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—skin cancer	6.55e-06	4.1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—skin cancer	6.55e-06	4.1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—skin cancer	6.55e-06	4.1e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—skin cancer	6.43e-06	4.03e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—skin cancer	6.43e-06	4.03e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—skin cancer	6.37e-06	3.99e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—skin cancer	6.36e-06	3.98e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—skin cancer	6.34e-06	3.97e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—skin cancer	6.28e-06	3.93e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO2—skin cancer	6.27e-06	3.92e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BRAF—skin cancer	6.2e-06	3.88e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—skin cancer	6.1e-06	3.82e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—skin cancer	6.1e-06	3.82e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—skin cancer	6.09e-06	3.81e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—skin cancer	6.09e-06	3.81e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—skin cancer	6.07e-06	3.8e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—skin cancer	6.07e-06	3.8e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—skin cancer	6.05e-06	3.79e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—skin cancer	6.03e-06	3.77e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ERCC2—skin cancer	5.91e-06	3.7e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—skin cancer	5.86e-06	3.67e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—skin cancer	5.81e-06	3.64e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—skin cancer	5.81e-06	3.64e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—skin cancer	5.79e-06	3.62e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—skin cancer	5.63e-06	3.53e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ERCC2—skin cancer	5.57e-06	3.49e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—skin cancer	5.56e-06	3.48e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—skin cancer	5.53e-06	3.47e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—skin cancer	5.41e-06	3.39e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—skin cancer	5.37e-06	3.36e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—skin cancer	5.25e-06	3.29e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—skin cancer	5.24e-06	3.28e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—skin cancer	5.19e-06	3.25e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—skin cancer	5.01e-06	3.14e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—skin cancer	4.98e-06	3.12e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—skin cancer	4.92e-06	3.08e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—skin cancer	4.79e-06	3e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—skin cancer	4.79e-06	3e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—skin cancer	4.77e-06	2.98e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—skin cancer	4.7e-06	2.95e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—skin cancer	4.69e-06	2.94e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—skin cancer	4.67e-06	2.92e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—skin cancer	4.66e-06	2.92e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—skin cancer	4.62e-06	2.89e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—skin cancer	4.6e-06	2.88e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—skin cancer	4.58e-06	2.87e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—skin cancer	4.5e-06	2.82e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—skin cancer	4.46e-06	2.8e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—skin cancer	4.45e-06	2.79e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—skin cancer	4.41e-06	2.76e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—skin cancer	4.4e-06	2.76e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—skin cancer	4.4e-06	2.75e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—skin cancer	4.27e-06	2.68e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—skin cancer	4.26e-06	2.67e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—skin cancer	4.22e-06	2.64e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—skin cancer	4.11e-06	2.57e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—skin cancer	4.07e-06	2.55e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—skin cancer	4.07e-06	2.55e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—skin cancer	3.93e-06	2.46e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—skin cancer	3.9e-06	2.44e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—skin cancer	3.9e-06	2.44e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—skin cancer	3.79e-06	2.37e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—skin cancer	3.76e-06	2.35e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ERCC2—skin cancer	3.64e-06	2.28e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—skin cancer	3.54e-06	2.22e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—skin cancer	3.37e-06	2.11e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—skin cancer	3.35e-06	2.1e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—skin cancer	3.34e-06	2.09e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—skin cancer	3.22e-06	2.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—skin cancer	3.08e-06	1.93e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—skin cancer	2.98e-06	1.87e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—skin cancer	2.85e-06	1.78e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—skin cancer	2.73e-06	1.71e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—skin cancer	2.18e-06	1.37e-05	CbGpPWpGaD
